I am a breastfeeding mother and i want to know if it is safe to use XRP6976? Is XRP6976 safe for nursing mother and child? Does XRP6976 extracts into breast milk? Does XRP6976 has any long term or short term side effects on infants? Can XRP6976 influence milk supply or can XRP6976 decrease milk supply in lactating mothers?
- DrLact safety Score for XRP6976 is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of XRP6976 may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that XRP6976 may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using XRP6976 .
- Usage of XRP6976 is in contradiction to breastfeeding hence if it is must to use XRP6976 and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Drug is cleared from the body in 10 elimination half-lives. Resuming breastfeeding is likely safe after 5 days of pumping-and-dumping.
Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy.[1] No information is available on the clinical use of XRP6976 during breastfeeding. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[2] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.
A telephone follow-up study was conducted on 74 women who received cancer chemotherapy at one center during the second or third trimester of pregnancy to determine if they were successful at breastfeeding postpartum. Only 34% of the women were able to exclusively breastfeed their infants, and 66% of the women reported experiencing breastfeeding difficulties. This was in comparison to a 91% breastfeeding success rate in 22 other mothers diagnosed during pregnancy, but not treated with chemotherapy. Other statistically significant correlations included: (1) mothers with breastfeeding difficulties had an average of 5.5 cycles of chemotherapy compared with 3.8 cycles among mothers who had no difficulties; and (2) mothers with breastfeeding difficulties received their first cycle of chemotherapy on average 3.4 weeks earlier in pregnancy. Of the 9 women who received a taxane-containing regimen, 7 had breastfeeding difficulties.[3]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.